$SXTC News

China SXT Pharmaceuticals Shares Surge Over 25% After Hours: Here's Why

China SXT Pharmaceuticals Files Prospectus To Offer Up To $100M Of Class A Ordinary Shares

China SXT Pharmaceuticals Sold 2M Shares For Gross Proceeds Of $760K On April 7, 2026

China SXT Pharmaceuticals Sold 2M Shares For Gross Proceeds Of $760K On April 7, 2026

China SXT Pharmaceuticals, Inc. Announces Share Re-classification

China SXT Pharmaceuticals Announces Share Reclassification Effective March 24th; Ordinary Shares To Be Reclassified As Class A Ordinary Shares, Trade Under Symbol "SXTC"

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

China SXT Pharmaceuticals shares are trading lower after the company announced a 1-for-150 reverse stock split.

China SXT Pharmaceutics Announces 1-For-150 Reverse Stock Split, Effective Feb. 3

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

China SXT Pharmaceuticals Announces AI Insight Initiative To Mull Application Of AI, Related Digital Technologies Across Traditional Chinese Medicine Raw Material Supply Chain

Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT

China SXT Launches Strategic AI Insights Initiative; Plans To Strategically Develop And Operate A Series Of Offline AI-Supported Traditional Chinese Medicine Consultation Stores Across China

China SXT Pharmaceuticals Shares Resume Trade

China SXT Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Down -18.12%

China SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)

Uncovering US Market's Undiscovered Gems In July 2025